Background Prescription information for many drugs entering the market lacks dosage
guidance for hepatic impairment. Dedicated studies for assessing the fate of drugs in hepatic …

Nonalcoholic fatty liver disease (NAFLD), representing a clinical spectrum ranging from
nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), is rapidly evolving …

Liver cirrhosis is a chronic disease that affects the liver structure, protein expression, and
overall metabolic function. Abundance data for drug-metabolizing enzymes and transporters …

Biologics address a range of unmet clinical needs, but the occurrence of biologics-induced
liver injury remains a major challenge. Development of cimaglermin alfa (GGF2) was …

Biologics are a fast-growing therapeutic class, with intertwined pharmacokinetics and
pharmacodynamics, affected by the abundance and function of the FcRn receptor. While …

Abstract Model-based assessment of drug pharmacokinetics in liver disease requires
quantification of abundance and disease-related changes in hepatic enzymes and …

Chronic intraperitoneal injection of thioacetamide (TAA) in rats has been used as an animal
model of human cirrhosis to study the effects of the disease on drug metabolism. However …

Despite the extensive research conducted on the relationship between transforming growth
factor-beta 1 (TGF-β1) polymorphisms and levels and the onset and development of liver …

Objectives Malaria-induced alteration of physiological parameters and pharmacokinetic
properties of antimalarial drugs may be clinically relevant. Whether and how malaria alters …

The physiologically based pharmacokinetic (PBPK) approach can be used to develop
mathematical models for predicting the absorption, distribution, metabolism, and elimination …